Congress should make sure savings on medicines go to patients, not PBMs. https://lnkd.in/eg_x6As7
PhRMA
Pharmaceutical Manufacturing
Washington, District of Columbia 59,500 followers
Research. Progress. Hope.
About us
Our Mission: The Pharmaceutical Research & Manufacturers of America (PhRMA) has as its mission to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients by pharmaceutical and biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving these goals in Washington, the states and the world: Broad patient access to safe and effective medicines through a free market, without price controls; Strong intellectual property incentives; And transparent, effective regulation and a free flow of information to patients. Who We Are: The Pharmaceutical Research and Manufacturers of America (PhRMA) represents innovative biopharmaceutical research and discovery companies. PhRMA is devoted to advancing public policies in the U.S. and around the world that support innovative medical research, yield progress for patients today and provide hope for the treatments and cures of tomorrow. Key Facts about the Biopharmaceutical Industry: - Since 2000, PhRMA member companies have invested more than $900 billion in the search for new treatments and cures. - America’s biopharmaceutical industry is the global leader in medical innovation, with more than 500 new medicines approved by the Food and Drug Administration since 2000. - The biopharmaceutical pipeline has over 7,000 new medicines currently in development around the world. Get fresh content daily by subscribing to our updates at https://catalyst.phrma.org/subscribe
- Website
-
https://www.PhRMA.org
External link for PhRMA
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Washington, District of Columbia
- Type
- Nonprofit
- Founded
- 1958
- Specialties
- Policy, Scientific Research, Advocacy, Public Affairs, Federal Affairs, State Government Affairs, and pharmaceuticals
Locations
-
Primary
670 Maine Ave SW
Washington, District of Columbia 20024, US
Employees at PhRMA
Updates
-
Equitable Breakthroughs in Medicine Development is broadening its impact with additional clinical trial sites: Atrium Health Wake Forest Baptist in Winston-Salem, NC, Health 360x which brings in 35 additional sites across 14 states, Southside Medical Center in Atlanta, GA, and UAB Minority Health & Health Equity Research Center in Birmingham, AL. Funded by a grant from PhRMA, this initiative aims to enhance clinical trial diversity and bring innovative treatments to more communities. Discover more about this effort: https://lnkd.in/e5TdcT6S
-
Preventing diseases before they occur is just as important as developing new treatments and cures. In a recent conversation, PhRMA's Chief Medical Officer Michael Ybarra, MD, joins Dr. Leonard Friedland, a pediatrician and Vice President and Director of Scientific and Public Affairs at GSK to explore how the industry is approaching prevention. https://lnkd.in/ekrxyXVC
Improving Cancer Patient Access
-
“Most of the policies that are talked about in Washington don't trickle down to that bedside encounter that I'm having with a patient face to face.” Hear from Michael Ybarra, MD on policy’s role in improving cancer patient access and lowering out-of-pocket medicine costs.
Improving Cancer Patient Access
-
Since first reported in the early 1980s, HIV/AIDS has gone from a death sentence to a manageable condition with a normal life expectancy. While we're proud of the progress made in the fight against HIV/AIDS, there's still more work to be done. Learn more as we commemorate #WorldAIDSDay: https://lnkd.in/eHKADeg8
-
State auditors in Minnesota released today a 340B report that paints a stark picture. Eligible hospitals and clinics in the state made at least $630 million in 340B profits in 2023. Hospitals are marking up the price of medicines with little charity care rates to show and the program’s benefit to patients remains unclear. Even worse, the report states that this figure is likely as little as half of the actual total 340B profits for eligible Minnesota providers. What’s worse, middlemen siphoned more than $120 million from the program, representing $16 out of every $100 of 340B dollars. Large hospitals, big pharmacies, PBMs and others rake in huge profits while patients, taxpayers and employers foot the bill. While this level of clarity is sorely needed in 340B, the important question of how Minnesota patients – and patients in states across the country – benefit from this program remains. https://lnkd.in/eGgdjwiJ
-
American Enterprise Institute Nonresident Fellow Kirsten Axelsen discusses the significance of cross-sector collaboration in developing innovative cancer medicines and how recent policies endanger these valuable relationships.
-
Antibiotic-resistant infections are directly associated with over 1.2 million deaths per year. Without intervention, the threat of antimicrobial resistance (AMR) will only continue to grow. Vaccines are our greatest tool against evolving public health threats like AMR. If rolled out for all 23 evaluated pathogens in recent World Health Organization research, vaccines could reduce the number of antibiotics needed by 22% every year, and save one-third of the hospital costs associated with AMR. #WAAW #AMR https://lnkd.in/g37jBnY9
-
As an industry, we’ve made incredible progress in transforming diabetes care over the past century. This #AmericanDiabetesMonth, we recognize the important role innovation plays in improving the health of patients living with the disease and understand the critical need for a policy environment that prioritizes affordable access to life-saving diabetes treatments. Hear more from PhRMA’s Senior Director of Public Affairs & Strategic Initiatives, Drew Voytal, MPA-HCA, who has lived with type 1 diabetes for most of his life:
-
The biopharmaceutical industry is projected to spend over $100 billion a year to bring new medicines to patients, but 4 in 10 patients still face issues accessing the treatments they need. On November 21, PhRMA’s Chief Operating Officer, Lori Reilly will participate in a WTOP News webinar about the barriers to medicines imposed by middlemen and the legislative action needed to protect patient access. Register to watch here: https://lnkd.in/epr9uKV6
WTOP’s The Health Care Agenda 2024 - WTOP News
https://wtop.com